We are a radiopharmaceutical company dedicated to developing a new class of personalized alpha-particle theranostics
Viewpoint Molecular Targeting® is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. Viewpoint’s leading lead-212-based alpha-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Viewpoint is also developing complementary imaging diagnostics that utilize the same targeting peptide for the purpose of personalizing treatment and optimizing patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.
The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-𝛼-NET) programs are entering Phase 1 imaging studies, to be followed by Phase 1/2a therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at two leading academic institutions.
We are a radiopharmaceutical company devoted to the rapid development of targeted alpha-particle therapies with the power to cure cancer for patients
Viewpoint Molecular Targeting aspires to be the global leader in the development and delivery of life-saving targeted alpha-particle radiotherapies for cancer